Description

Strain Information

Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered Mutant Mice. Mating System Homozygote x Homozygote         (Female x Male) Species laboratory mouse Generation N12+F3 (08-JAN-08)   Donating Investigator Menno de Winther,   Maastricht University

Description
Mice homozygous for the Nfkb1^tm1Bal targeted mutation are viable and fertile. Homozygous mutant mice exhibit defective B cell responses, defective responses to infection, and also defects in basal and specific antibody production. These mice may be useful in studies of inflammation and immune responses and signal transduction.

In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. This is the case for the strain above. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.

Development
A targeting vector containing the PGK-neo resistance gene in opposite transcriptional orientation was designed to disrupt exon 6 of the endogenous gene. The construct was electroporated into 129P2/OlaHsd-derived E14 embryonic stem (ES) cells. Correctly targeted ES cells were injected into C57BL/6J blastocysts amd the resulting chimeric mice were crossed with C57BL/6J mice. Heterozygous mice were bred to create homozygous mice on a mixed B6;129P2 background prior to arrival at The Jackson Laboratory. Dr. Menno de Winther of Maastricht University, The Netherlands obtained JR#002849 from The Jackson Laboratory and backcrossed them to C57BL/6JIco for 12 generations.

Control Information

	Control
	000664 C57BL/6J	(approximate)
Considerations for Choosing Controls

Related Strains

Strains carrying   Nfkb1^tm1Bal allele

002849

B6;129P-Nfkb1tm1Bal/J

View Strains carrying   Nfkb1^tm1Bal     (1 strain)

Additional Web Information

Congenic Nomenclature

Phenotype

Phenotype Information

View Mammalian Phenotype Terms

Mammalian Phenotype Terms

      assigned by genotype

The following phenotype information may relate to a genetic background differing from this JAX^® Mice strain.

Nfkb1^tm1Bal/Nfkb1^tm1Bal

        Background Not Specified

• immune system phenotype
• abnormal Peyer's patch morphology (MGI Ref ID J:77049)
  • increased CD3⁺ T cell count, resulting in decreased B220⁺ B cells/CD3⁺ T cell ratio
• abnormal Peyer's patch follicle morphology (MGI Ref ID J:77049)
  • while follicles were clearly demarcated at E13.5, they were reduced in number and in size
• decreased Peyer's patch number (MGI Ref ID J:77049)
  • average of 2 to 4 Peyer's patches per mouse compared to an observed average of 7 to 10 per control mouse

Nfkb1^tm1Bal/Nfkb1^tm1Bal

        B6;129P-Nfkb1^tm1Bal/J

• hearing/vestibular/ear phenotype
• abnormal cochlear inner hair cell morphology (MGI Ref ID J:107245)
  • at 1 and 3 months, vacuole-like spaces replace the afferent terminals of the inner radial nerves while efferent inner spiral fibers appear intact
  • at 1 and 3 months, edematous-appearing extracellular spaces are noted between the IHC and supporting cells; the cytoplasm in the base of IHCs consists of numerous small vesicles infiltrated with mitochondria and short profiles of cisternae
  • in contrast, no major pathological changes are seen in mutant OHCs or stria vascularis at 1 or 3 months
  • all homozygotes (6 of 6) exhibit excitotoxic pathologies of afferent dendrites under the IHCs compared with 4 of 9 in wild-type mice
  • homozygotes show a significantly higher number of swollen dendritic terminals per IHC region relative to wild-type mice; only type I ganglion neurons are involved
• decreased cochlear nerve compound action potential (MGI Ref ID J:107245)
  • at 1 month of age, CAP thresholds in homozygotes are elevated by 6-20 dB SPL relative to wild-type mice at almost all frequencies
  • at 3 months of age, mutant CAP thresholds are increased by ~20 dB SPL at low frequencies and by ~30 dB at high frequencies relative to wild-type
  • by 8 months of age, most homozygotes no longer respond to auditory stimuli at high frequencies (90 dB SPL), whereas wild-type mice retain CAP responses at most test frequencies
  • at 3 months, no sigificant loss of distorion product otoacoustic emissions (DPOAEs) is noted when primaries are presented at 70 dB SPL
  • no significant differences in mean endocochlear potential values are observed at 1, 3, and 8 months of age relative to wild-type mice
• increased susceptibility to age-related hearing loss (MGI Ref ID J:107245)
  • homozygotes exhibit accelerated age-related hearing loss at higher frequencies, as assessed by CAP threshold shifts at 1, 3, and 8 months of age
  • accelerated hearing loss is highly associated with an exacerbated excitotoxic-like damage in afferent dendrites under IHCs and an accelerated loss of spiral ganglion neurons
• increased susceptibility to noise-induced hearing loss (MGI Ref ID J:107245)
  • at 2 hrs after exposure to a wideband, low-level noise at 70 dB SPL, 1-month-old homozygotes display 7-15 dB SPL threshold shifts across most test frequencies whereas wild-type mice show no significant CAP threshold shifts
• nervous system phenotype
• abnormal cochlear inner hair cell morphology (MGI Ref ID J:107245)
  • at 1 and 3 months, vacuole-like spaces replace the afferent terminals of the inner radial nerves while efferent inner spiral fibers appear intact
  • at 1 and 3 months, edematous-appearing extracellular spaces are noted between the IHC and supporting cells; the cytoplasm in the base of IHCs consists of numerous small vesicles infiltrated with mitochondria and short profiles of cisternae
  • in contrast, no major pathological changes are seen in mutant OHCs or stria vascularis at 1 or 3 months
  • all homozygotes (6 of 6) exhibit excitotoxic pathologies of afferent dendrites under the IHCs compared with 4 of 9 in wild-type mice
  • homozygotes show a significantly higher number of swollen dendritic terminals per IHC region relative to wild-type mice; only type I ganglion neurons are involved
• cochlear ganglion degeneration (MGI Ref ID J:107245)
  • at 8 months, homozygotes show a 69% loss of SGNs in the basal cochlea relative to a ~28% loss observed in wild-type mice
  • at 8 months, the numbers of afferent axons per habenular opening are significantly reduced relative to those of wild-type mice
  • however, no significant differences in IHC or OHC loss are noted at 8 months relative to wild-type mice
• decreased cochlear nerve compound action potential (MGI Ref ID J:107245)
  • at 1 month of age, CAP thresholds in homozygotes are elevated by 6-20 dB SPL relative to wild-type mice at almost all frequencies
  • at 3 months of age, mutant CAP thresholds are increased by ~20 dB SPL at low frequencies and by ~30 dB at high frequencies relative to wild-type
  • by 8 months of age, most homozygotes no longer respond to auditory stimuli at high frequencies (90 dB SPL), whereas wild-type mice retain CAP responses at most test frequencies
  • at 3 months, no sigificant loss of distorion product otoacoustic emissions (DPOAEs) is noted when primaries are presented at 70 dB SPL
  • no significant differences in mean endocochlear potential values are observed at 1, 3, and 8 months of age relative to wild-type mice
• homeostasis/metabolism phenotype
• *normal* homeostasis/metabolism phenotype (MGI Ref ID J:91366)
  • despite altered expression of Trp53, neurons exhibit normal camptothecin-induced neuronal death
• abnormal calcium ion homeostasis (MGI Ref ID J:107245)
  • at 8 months, the immunoreactivity for a set of calcium-buffering proteins is significantly increased in mutant spiral ganglion neurons, suggesting impaired calcium ion homeostasis
• immune system phenotype
• *normal* immune system phenotype (MGI Ref ID J:118907)
  • most pancreatic islet cells appear normal in mutants not developing diabetes after streptozotocin treatment, while control pancreatic islets display insulitis; mutants developing diabetes after treatment display insulis in many islets
• abnormal CD4-positive T cell physiology (MGI Ref ID J:118907)
  • splenocytes treated with anti-CD3 with or without anti-CD28 antibodies produce reduced levels of interferon gamma and Il-2 (Th1 cytokines) but increased levels of Il-4 and Il-10 (Th2 cytokines) while wild-type splenocytes produce both Th1 and Th2 cytokines
• abnormal antigen presenting cell physiology (MGI Ref ID J:118907)
• abnormal dendritic cell physiology (MGI Ref ID J:118907)
  • bone marrow-derived dendritic cells stimulated with LPS produce significantly less Il-12p40 and TNF alpha than stimulated wild-type dendritic cells
• abnormal macrophage physiology (MGI Ref ID J:118907)
  • peritoneal macrophages produce less Il-6, Il-12p40, TNF alpha, and nitric oxide compared to wild-type cells upon stimulation with interferon gamma and/or LPS
• abnormal cytokine secretion (MGI Ref ID J:79107)
  • Il-4 secretion is impaired in cultured cells upon stimulation with MOG peptide
• decreased susceptibility to autoimmune diabetes (MGI Ref ID J:118907)
  • >70% of control mice treated with low dose streptozotocin for 5 days develop diabetes starting ~8 and 12 days after the first injection, but only 23% of mutants develop diabetes
• cellular phenotype
• increased apoptosis (MGI Ref ID J:118907)
  • growth factor withdrawal from cultured bone marrow dendritic cells enhances apoptosis of dendritic cells, but not granulocytes or macrophages
• muscle phenotype
• *normal* muscle phenotype (MGI Ref ID J:135692)
  • myogenesis is normal

Nfkb1^tm1Bal/Nfkb1^tm1Bal

        involves: 129P2/OlaHsd * C57BL/6

• life span-post-weaning/aging
• abnormal induced morbidity/mortality (MGI Ref ID J:37184)
  • mice die 24 hours after infection with Staphylococcus pneumoniae compared to wild-type mice that die between 36 and 72 hours after infection
• premature death (MGI Ref ID J:37184)
  • mice die more frequently at a young age compared to wild-type mice
• immune system phenotype
• abnormal class switch recombination (MGI Ref ID J:30268)
  • B cells are defective in IgG3, IgE and IgA class switching but undergo substantial IgG1 class switching
• abnormal humoral immune response (MGI Ref ID J:37184)
  • total NP-binding following exposure to NP15-CG is lower than in wild-type mice and NP-specific antibodies of all isotypes are decreased compared to in wild-type mice
• decreased immunoglobulin level (MGI Ref ID J:37184)
  • immunoglobin levels are 4-fold lower than in wild-type mice
  • all isotypes except IgM are reduced
• decreased IgA level (MGI Ref ID J:37184)
  • IgA levels are decreased 5-fold
• decreased IgE level (MGI Ref ID J:37184)
  • IgE levels are decreased 50-fold
• decreased IgG1 level (MGI Ref ID J:37184)
  • IgG1 levels are reduced 10-fold
• decreased IgM level (MGI Ref ID J:30268)
  • proliferating B cells stimulated with alpha-delta-dex and IL-4 + IL-5 produce 32-fold less IgM than wild-type
  • proliferating B cells stimulated wth mCD40L + IL-4 + IL-5 produce 41-fold less IgM than wild-type
  • however, mlg and CD40 signaling restores B cell maturation to IgM secretion
• decreased B cell proliferation (MGI Ref ID J:37184)
  • B cells do not proliferate in response to LPS concentration that stimulate wild-type B cells to proliferate
  • B cell proliferation following LPS and sCD40L stimulation is impaired
  • however, B cells proliferate normally in response to CD40L, alpha-delta-dex and IL-4 + IL-5
• decreased interleukin-6 secretion (MGI Ref ID J:37184)
  • LPS-stimulated macrophages release 6-fold less IL-6
• decreased susceptibility to viral infection (MGI Ref ID J:37184)
  • mice are more resistant to EMC virus infection than wild-type mice and exhibit mortality at a 10-fold higher titer with a slower progression towards fatal encephalopathy
• increased susceptibility to infection (MGI Ref ID J:37184)
  • mice are more prone to infection than wild-type mice
  • while mice efficiently clear extracellular bacteria they fail to clear intracellular bacteria
  • 6 days after infection with Listeria monocytogenes, mice exhibit no peritoneal bacterial but several thousand splenic bacteria compared to wild-type mice that exhibit neither
  • mice die 24 hours after infection with Staphylococcus pneumoniae compared to wild-type mice that die between 36 and 72 hours after infection
  • however, mice do not exhibit any abnormal response to H. influenzae and E. coli infection
• increased susceptibility to bacterial infection (MGI Ref ID J:67107)
  • mice are more sensitive to typhlocolitis induced by H. hepaticus than wild-type mice but less sensitive than Nfkb1^tm1Bal/Nfkb1^tm1Bal Rela^tm1Bal/Rela⁺
• large intestinal inflammation (MGI Ref ID J:67107)
  • mice exhibit mild typhlocolitis
• peritoneal inflammation (MGI Ref ID J:67107)
  • mild
• digestive/alimentary phenotype
• abnormal cecum morphology (MGI Ref ID J:67107)
  • mice exhibit mild typhlocolitis
• abnormal colon morphology (MGI Ref ID J:67107)
  • mice exhibit mild colonic perforations and typhlocolitis
• diarrhea (MGI Ref ID J:67107)
  • mild
• large intestinal inflammation (MGI Ref ID J:67107)
  • mice exhibit mild typhlocolitis
• peritoneal inflammation (MGI Ref ID J:67107)
  • mild
• hematopoietic system phenotype
• abnormal class switch recombination (MGI Ref ID J:30268)
  • B cells are defective in IgG3, IgE and IgA class switching but undergo substantial IgG1 class switching
• decreased B cell proliferation (MGI Ref ID J:37184)
  • B cells do not proliferate in response to LPS concentration that stimulate wild-type B cells to proliferate
  • B cell proliferation following LPS and sCD40L stimulation is impaired
  • however, B cells proliferate normally in response to CD40L, alpha-delta-dex and IL-4 + IL-5

Nfkb1^tm1Bal/Nfkb1^tm1Bal

        involves: 129P2/OlaHsd

• immune system phenotype
• *normal* immune system phenotype (MGI Ref ID J:113514)
  • mice exhibit normal dendritic cell development and maturation
• decreased marginal zone B cell number (MGI Ref ID J:65246)
• hematopoietic system phenotype
• decreased marginal zone B cell number (MGI Ref ID J:65246)

View Research Applications

Research Applications

This mouse can be used to support research in many areas including:

Cell Biology Research
Signal Transduction
Transcriptional Regulation

Immunology and Inflammation Research

Nfkb1^tm1Bal related

Immunology and Inflammation Research
Immunodeficiency (Inflammatory bowel disease)

Genes & Alleles

Gene & Allele Information

Allele Symbol		Nfkb1tm1Bal
Allele Name		targeted mutation 1, David Baltimore
Allele Type		Targeted (knock-out)
Common Name(s)		NF-kappaB1 KO; NF-kappaB1-; NF-kappaBtm1Bal; NFkappaB10; Nfkappab1-; Nfkb1-; p50-; p50KO;
Mutation Made By		David Baltimore,   California Institute of Technology
Strain of Origin		129P2/OlaHsd
ES Cell Line Name		E14
ES Cell Line Strain		129P2/OlaHsd
Gene Symbol and Name		Nfkb1, nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, p105
Chromosome		3
Gene Common Name(s)		DKFZp686C01211; EBP-1; KBF1; MGC54151; NF kappaB1; NF-kB; NF-kappa-B; NF-kappaB; NFKB-p105; NFKB-p50; nuclear factor kappaB p50; p105; p50; p50 subunit of NF kappaB; p50/p105;
General Note		Effect of reconstitution with Nfkb1tm1Bal homozygous hematopoietic cells on atherogenesis in atherosclerosis prone mice To assess the role of NFKB1 in atherogenesis, mice homozygous for a mutation of the low density lipoprotein receptor (Ldlrtm1Her) were lethally irradiated and transplanted with bone marrow from Nfkb1tm1Bal homozygous mice and 4 weeks later placed on a high-fat diet for 10 weeks. Aortic root lesion area of mice with NFKB1-deficient hematopoietic cells was 41% smaller than in control mice. Whereas control lesions contained primarily large foam cells, lesions of mice reconstituted with NFKB1-deficient bone marrow contained large numbers of small, inflammatory cells and very few foam cells. 3-fold as many cells attached to the lesion cap in transplanted mice. Most cells in control lesions were macrophages, while in transplanted mice there was a preponderance of T and B lymphocytes. Macrophages induced to differentiate in culture from NFKB1-deficient bone marrow exhibited differences versus control macrophages in the secretion patterns of several cytokines following lipopolysaccharide (LPS) stimulation. Whereas control macrophages expressed high levels of scavenger receptor class A (SR-A) in response to LPS, this response was greatly attenuated in mice with NFKB1-deficient hematopoietic systems; uptake of oxidized low density lipoprotein (oxLDL) was similarly diminished, although neither parameter differed between transplant and control macrophages in the absence of stimulation. J:87639
Molecular Note		Insertion of a PGK-neomycin resistance cassette into exon 6 disrupted the gene. Exon 6 encodes the p105 precursor of the p50 subunit of the encoded transcription factor. The authors predict that this allele produces a truncated polypeptide that cannot bind with DNA, or dimerize with itself or other kappaB binding motifs. [MGI Ref ID J:37184]

Genotyping

Genotyping Information

Genotyping Protocols

Nfkb1^tm1Bal, STD PCR, vers. 1

Helpful Links

Optimizing PCR Protocols

References

References

Additional References

Nfkb1^tm1Bal related

Acharyya S; Villalta SA; Bakkar N; Bupha-Intr T; Janssen PM; Carathers M; Li ZW; Beg AA; Ghosh S; Sahenk Z; Weinstein M; Gardner KL; Rafael-Fortney JA; Karin M; Tidball JG; Baldwin AS; Guttridge DC. 2007. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 117(4):889-901. [PubMed: 17380205]  [MGI Ref ID J:121279]

Aleyasin H; Cregan SP; Iyirhiaro G; O'Hare MJ; Callaghan SM; Slack RS; Park DS. 2004. Nuclear factor-(kappa)B modulates the p53 response in neurons exposed to DNA damage. J Neurosci 24(12):2963-73. [PubMed: 15044535]  [MGI Ref ID J:90221]

Altavilla D; Famulari C; Passaniti M; Galeano M; Macri A; Seminara P; Minutoli L; Marini H; Calo M; Venuti FS; Esposito M; Squadrito F. 2003. Attenuated cerulein-induced pancreatitis in nuclear factor-kappaB-deficient mice. Lab Invest 83(12):1723-32. [PubMed: 14691290]  [MGI Ref ID J:87079]

Artis D; Kane CM; Fiore J; Zaph C; Shapira S; Joyce K; Macdonald A; Hunter C; Scott P; Pearce EJ. 2005. Dendritic cell-intrinsic expression of NF-kappaB1 is required to promote optimal Th2 cell differentiation. J Immunol 174(11):7154-9. [PubMed: 15905559]  [MGI Ref ID J:99003]

Artis D; Shapira S; Mason N; Speirs KM; Goldschmidt M; Caamano J; Liou HC; Hunter CA; Scott P. 2002. Differential requirement for NF-kappaB family members in control of helminth infection and intestinal inflammation. J Immunol 169(8):4481-7. [PubMed: 12370384]  [MGI Ref ID J:79531]

Artis D; Speirs K; Joyce K; Goldschmidt M; Caamano J; Hunter CA; Scott P. 2003. NF-kappa B1 is required for optimal CD4+ Th1 cell development and resistance to Leishmania major. J Immunol 170(4):1995-2003. [PubMed: 12574369]  [MGI Ref ID J:106657]

Bakkar N; Wang J; Ladner KJ; Wang H; Dahlman JM; Carathers M; Acharyya S; Rudnicki MA; Hollenbach AD; Guttridge DC. 2008. IKK/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis. J Cell Biol 180(4):787-802. [PubMed: 18299349]  [MGI Ref ID J:135692]

Beg AA; Baltimore D. 1996. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death [see comments] Science 274(5288):782-4. [PubMed: 8864118]  [MGI Ref ID J:36492]

Bohuslav J; Kravchenko VV; Parry GC; Erlich JH; Gerondakis S; Mackman N; Ulevitch RJ. 1998. Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. J Clin Invest 102(9):1645-52. [PubMed: 9802878]  [MGI Ref ID J:115230]

Campbell IK; Gerondakis S; O'Donnell K; Wicks IP. 2000. Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 105(12):1799-806. [PubMed: 10862795]  [MGI Ref ID J:120528]

Cao S; Zhang X; Edwards JP; Mosser DM. 2006. NF-kappaB1 (p50) homodimers differentially regulate pro- and anti-inflammatory cytokines in macrophages. J Biol Chem 281(36):26041-50. [PubMed: 16835236]  [MGI Ref ID J:117172]

Cariappa A; Liou HC; Horwitz BH; Pillai S. 2000. Nuclear factor kappaB is required for the development of marginal zone B lymphocytes J Exp Med 192(8):1175-82. [PubMed: 11034607]  [MGI Ref ID J:65246]

Dadgostar H; Zarnegar B; Hoffmann A; Qin XF; Truong U; Rao G; Baltimore D; Cheng G. 2002. Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci U S A 99(3):1497-502. [PubMed: 11830667]  [MGI Ref ID J:126969]

Das G; Augustine MM; Das J; Bottomly K; Ray P; Ray A. 2003. An important regulatory role for CD4+CD8 alpha alpha T cells in the intestinal epithelial layer in the prevention of inflammatory bowel disease. Proc Natl Acad Sci U S A 100(9):5324-9. [PubMed: 12695566]  [MGI Ref ID J:83283]

Das J; Chen CH; Yang L; Cohn L; Ray P; Ray A. 2001. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immunol 2(1):45-50. [PubMed: 11135577]  [MGI Ref ID J:124693]

DeAngelis RA; Kovalovich K; Cressman DE; Taub R. 2001. Normal liver regeneration in p50/nuclear factor kappaB1 knockout mice. Hepatology 33(4):915-24. [PubMed: 11283856]  [MGI Ref ID J:106562]

Demarchi F; Bertoli C; Greer PA; Schneider C. 2005. Ceramide triggers an NF-kappaB-dependent survival pathway through calpain. Cell Death Differ 12(5):512-22. [PubMed: 15933726]  [MGI Ref ID J:111869]

Denis-Donini S; Dellarole A; Crociara P; Francese MT; Bortolotto V; Quadrato G; Canonico PL; Orsetti M; Ghi P; Memo M; Bonini SA; Ferrari-Toninelli G; Grilli M. 2008. Impaired adult neurogenesis associated with short-term memory defects in NF-kappaB p50-deficient mice. J Neurosci 28(15):3911-9. [PubMed: 18400889]  [MGI Ref ID J:134332]

Dennis A; Kudo T; Kruidenier L; Girard F; Crepin VF; MacDonald TT; Frankel G; Wiles S. 2008. The p50 subunit of NF-kappaB is critical for in vivo clearance of the noninvasive enteric pathogen Citrobacter rodentium. Infect Immun 76(11):4978-88. [PubMed: 18694964]  [MGI Ref ID J:140394]

Duckworth EA; Butler T; Collier L; Collier S; Pennypacker KR. 2006. NF-kappaB protects neurons from ischemic injury after middle cerebral artery occlusion in mice. Brain Res 1088(1):167-175. [PubMed: 16630592]  [MGI Ref ID J:109667]

Dumitru CD; Ceci JD; Tsatsanis C; Kontoyiannis D; Stamatakis K; Lin JH; Patriotis C; Jenkins NA; Copeland NG; Kollias G; Tsichlis PN. 2000. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103(7):1071-83. [PubMed: 11163183]  [MGI Ref ID J:66503]

Enzler T; Bonizzi G; Silverman GJ; Otero DC; Widhopf GF; Anzelon-Mills A; Rickert RC; Karin M. 2006. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 25(3):403-15. [PubMed: 16973390]  [MGI Ref ID J:113556]

Erdman S; Fox JG; Dangler CA; Feldman D; Horwitz BH. 2001. Typhlocolitis in NF-kappa B-deficient mice. J Immunol 166(3):1443-7. [PubMed: 11160181]  [MGI Ref ID J:67107]

Feng JQ; Xing L; Zhang JH; Zhao M; Horn D; Chan J; Boyce BF; Harris SE; Mundy GR; Chen D. 2003. NF-kappaB specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro. J Biol Chem 278(31):29130-5. [PubMed: 12759356]  [MGI Ref ID J:120693]

Franzoso G; Carlson L; Xing L; Poljak L; Shores EW; Brown KD; Leonardi A; Tran T; Boyce BF; Siebenlist U. 1997. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11(24):3482-96. [PubMed: 9407039]  [MGI Ref ID J:45119]

Gadjeva M; Tomczak MF; Zhang M; Wang YY; Dull K; Rogers AB; Erdman SE; Fox JG; Carroll M; Horwitz BH. 2004. A role for NF-kappaB subunits p50 and p65 in the inhibition of lipopolysaccharide-induced shock. J Immunol 173(9):5786-93. [PubMed: 15494531]  [MGI Ref ID J:93765]

Gadjeva M; Wang Y; Horwitz BH. 2007. NF-kappaB p50 and p65 subunits control intestinal homeostasis. Eur J Immunol 37(9):2509-17. [PubMed: 17705134]  [MGI Ref ID J:124335]

Glauert HP; Tharappel JC; Banerjee S; Chan NL; Kania-Korwel I; Lehmler HJ; Lee EY; Robertson LW; Spear BT. 2008. Inhibition of the promotion of hepatocarcinogenesis by 2,2',4,4',5,5'-hexachlorobiphenyl (PCB-153) by the deletion of the p50 subunit of NF-kappaB in mice. Toxicol Appl Pharmacol 232(2):302-8. [PubMed: 18644402]  [MGI Ref ID J:140058]

Gourzi P; Leonova T; Papavasiliou FN. 2007. Viral induction of AID is independent of the interferon and the Toll-like receptor signaling pathways but requires NF-kappaB. J Exp Med 204(2):259-65. [PubMed: 17242162]  [MGI Ref ID J:125375]

Grumont R; Hochrein H; O'Keeffe M; Gugasyan R; White C; Caminschi I; Cook W; Gerondakis S. 2001. c-Rel Regulates Interleukin 12 p70 Expression in CD8(+) Dendritic Cells by Specifically Inducing p35 Gene Transcription. J Exp Med 194(8):1021-32. [PubMed: 11602633]  [MGI Ref ID J:72212]

Grumont R; Lock P; Mollinari M; Shannon FM; Moore A; Gerondakis S. 2004. The mitogen-induced increase in T cell size involves PKC and NFAT activation of Rel/NF-kappaB-dependent c-myc expression. Immunity 21(1):19-30. [PubMed: 15345217]  [MGI Ref ID J:93602]

Grumont RJ; Gerondakis S. 2000. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor kappaB. J Exp Med 191(8):1281-92. [PubMed: 10770796]  [MGI Ref ID J:61726]

Grumont RJ; Rourke IJ; O'Reilly LA; Strasser A; Miyake K; Sha W; Gerondakis S. 1998. B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med 187(5):663-74. [PubMed: 9480976]  [MGI Ref ID J:46076]

Grumont RJ; Strasser A; Gerondakis S. 2002. B cell growth is controlled by phosphatidylinosotol 3-kinase-dependent induction of Rel/NF-kappaB regulated c-myc transcription. Mol Cell 10(6):1283-94. [PubMed: 12504005]  [MGI Ref ID J:125671]

Gugasyan R; Voss A; Varigos G; Thomas T; Grumont RJ; Kaur P; Grigoriadis G; Gerondakis S. 2004. The transcription factors c-rel and RelA control epidermal development and homeostasis in embryonic and adult skin via distinct mechanisms. Mol Cell Biol 24(13):5733-45. [PubMed: 15199130]  [MGI Ref ID J:91366]

Guo F; Tanzer S; Busslinger M; Weih F. 2008. Lack of nuclear factor-kappa B2/p100 causes a RelB-dependent block in early B lymphopoiesis. Blood 112(3):551-9. [PubMed: 18505785]  [MGI Ref ID J:138422]

Hilliard BA; Mason N; Xu L; Sun J; Lamhamedi-Cherradi SE; Liou HC; Hunter C; Chen YH. 2002. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest 110(6):843-50. [PubMed: 12235116]  [MGI Ref ID J:79107]

Hunot S; Vila M; Teismann P; Davis RJ; Hirsch EC; Przedborski S; Rakic P; Flavell RA. 2004. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101(2):665-70. [PubMed: 14704277]  [MGI Ref ID J:87428]

Hunter RB; Kandarian SC. 2004. Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J Clin Invest 114(10):1504-11. [PubMed: 15546001]  [MGI Ref ID J:94424]

Inan MS; Tolmacheva V; Wang QS; Rosenberg DW; Giardina C. 2000. Transcription factor NF-kappaB participates in regulation of epithelial cell turnover in the colon. Am J Physiol Gastrointest Liver Physiol 279(6):G1282-91. [PubMed: 11093952]  [MGI Ref ID J:108661]

Jhaveri KA; Ramkumar V; Trammell RA; Toth LA. 2006. Spontaneous, homeostatic, and inflammation-induced sleep in NF-kappaB p50 knockout mice. Am J Physiol Regul Integr Comp Physiol 291(5):R1516-26. [PubMed: 16793936]  [MGI Ref ID J:115796]

Jhaveri KA; Reichensperger J; Toth LA; Sekino Y; Ramkumar V. 2007. Reduced basal and lipopolysaccharide-stimulated adenosine A1 receptor expression in the brain of nuclear factor-kappaB p50-/- mice. Neuroscience 146(1):415-26. [PubMed: 17350174]  [MGI Ref ID J:122052]

Jones RG; Saibil SD; Pun JM; Elford AR; Bonnard M; Pellegrini M; Arya S; Parsons ME; Krawczyk CM; Gerondakis S; Yeh WC; Woodgett JR; Boothby MR; Ohashi PS. 2005. NF-kappaB couples protein kinase B/Akt signaling to distinct survival pathways and the regulation of lymphocyte homeostasis in vivo. J Immunol 175(6):3790-9. [PubMed: 16148125]  [MGI Ref ID J:116725]

Kanters E; Gijbels MJ; van der Made I; Vergouwe MN; Heeringa P; Kraal G; Hofker MH; de Winther MP. 2004. Hematopoietic NF-kappaB1 deficiency results in small atherosclerotic lesions with an inflammatory phenotype. Blood 103(3):934-40. [PubMed: 14512319]  [MGI Ref ID J:87639]

Kassed CA; Herkenham M. 2004. NF-kappaB p50-deficient mice show reduced anxiety-like behaviors in tests of exploratory drive and anxiety. Behav Brain Res 154(2):577-84. [PubMed: 15313047]  [MGI Ref ID J:92318]

Kassed CA; Willing AE; Garbuzova-Davis S; Sanberg PR; Pennypacker KR. 2002. Lack of NF-kappaB p50 exacerbates degeneration of hippocampal neurons after chemical exposure and impairs learning. Exp Neurol 176(2):277-88. [PubMed: 12359170]  [MGI Ref ID J:78419]

Kawamura N; Kubota T; Kawano S; Monden Y; Feldman AM; Tsutsui H; Takeshita A; Sunagawa K. 2005. Blockade of NF-kappaB improves cardiac function and survival without affecting inflammation in TNF-alpha-induced cardiomyopathy. Cardiovasc Res 66(3):520-9. [PubMed: 15914117]  [MGI Ref ID J:133874]

Kawano S; Kubota T; Monden Y; Kawamura N; Tsutsui H; Takeshita A; Sunagawa K. 2005. Blockade of NF-kappaB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. Cardiovasc Res 67(4):689-98. [PubMed: 15921667]  [MGI Ref ID J:106602]

Kawano S; Kubota T; Monden Y; Tsutsumi T; Inoue T; Kawamura N; Tsutsui H; Sunagawa K. 2006. Blockade of NF-kappaB improves cardiac function and survival after myocardial infarction. Am J Physiol Heart Circ Physiol 291(3):H1337-44. [PubMed: 16632551]  [MGI Ref ID J:116338]

Keller U; Nilsson JA; Maclean KH; Old JB; Cleveland JL. 2005. Nfkb 1 is dispensable for Myc-induced lymphomagenesis. Oncogene 24(41):6231-40. [PubMed: 15940251]  [MGI Ref ID J:101764]

Kleinman ME; Yamada K; Takeda A; Chandrasekaran V; Nozaki M; Baffi JZ; Albuquerque RJ; Yamasaki S; Itaya M; Pan Y; Appukuttan B; Gibbs D; Yang Z; Kariko K; Ambati BK; Wilgus TA; DiPietro LA; Sakurai E; Zhang K; Smith JR; Taylor EW; Ambati J. 2008. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452(7187):591-7. [PubMed: 18368052]  [MGI Ref ID J:133772]

Kozak W; Wrotek S; Kozak A. 2006. Pyrogenicity of CpG-DNA in mice: role of interleukin-6, cyclooxygenases, and nuclear factor-kappaB. Am J Physiol Regul Integr Comp Physiol 290(4):R871-80. [PubMed: 16293680]  [MGI Ref ID J:115760]

Lamhamedi-Cherradi SE; Zheng S; Hilliard BA; Xu L; Sun J; Alsheadat S; Liou HC; Chen YH. 2003. Transcriptional regulation of type I diabetes by NF-kappa B. J Immunol 171(9):4886-92. [PubMed: 14568969]  [MGI Ref ID J:118907]

Lang H; Schulte BA; Zhou D; Smythe N; Spicer SS; Schmiedt RA. 2006. Nuclear factor kappaB deficiency is associated with auditory nerve degeneration and increased noise-induced hearing loss. J Neurosci 26(13):3541-50. [PubMed: 16571762]  [MGI Ref ID J:107245]

Li J; Lu Z; Li WL; Yu SP; Wei L. 2008. Cell death and proliferation in NF-kappaB p50 knockout mouse after cerebral ischemia. Brain Res 1230:281-9. [PubMed: 18657523]  [MGI Ref ID J:139961]

Liou HC; Hsia CY. 2003. Distinctions between c-Rel and other NF-kappaB proteins in immunity and disease. Bioessays 25(8):767-80. [PubMed: 12879447]  [MGI Ref ID J:84673]

Lo JC; Basak S; James ES; Quiambo RS; Kinsella MC; Alegre ML; Weih F; Franzoso G; Hoffmann A; Fu YX. 2006. Coordination between NF-kappaB family members p50 and p52 is essential for mediating LTbetaR signals in the development and organization of secondary lymphoid tissues. Blood 107(3):1048-55. [PubMed: 16195333]  [MGI Ref ID J:127591]

Lu Z; Lee EY; Robertson LW; Glauert HP; Spear BT. 2004. Effect of 2,2',4,4',5,5'-hexachlorobiphenyl (PCB-153) on hepatocyte proliferation and apoptosis in mice deficient in the p50 subunit of the transcription factor NF-kappaB. Toxicol Sci 81(1):35-42. [PubMed: 15201435]  [MGI Ref ID J:101504]

Lu ZY; Yu SP; Wei JF; Wei L. 2006. Age-related neural degeneration in nuclear-factor kappaB p50 knockout mice. Neuroscience 139(3):965-78. [PubMed: 16533569]  [MGI Ref ID J:108859]

Mabley JG; Hasko G; Liaudet L; Soriano F; Southan GJ; Salzman AL; Szabo C. 2002. NFkappaB1 (p50)-deficient mice are not susceptible to multiple low-dose streptozotocin-induced diabetes. J Endocrinol 173(3):457-64. [PubMed: 12065235]  [MGI Ref ID J:109745]

Medoff BD; Wain JC; Seung E; Jackobek R; Means TK; Ginns LC; Farber JM; Luster AD. 2006. CXCR3 and its ligands in a murine model of obliterative bronchiolitis: regulation and function. J Immunol 176(11):7087-95. [PubMed: 16709871]  [MGI Ref ID J:131767]

Minami M; Shimizu K; Okamoto Y; Folco E; Ilasaca ML; Feinberg MW; Aikawa M; Libby P. 2008. Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation. J Biol Chem 283(15):9692-703. [PubMed: 18270204]  [MGI Ref ID J:135247]

Niederberger E; Schmidtko A; Gao W; Kuhlein H; Ehnert C; Geisslinger G. 2007. Impaired acute and inflammatory nociception in mice lacking the p50 subunit of NF-kappaB. Eur J Pharmacol 559(1):55-60. [PubMed: 17217946]  [MGI Ref ID J:124506]

O'Keeffe M; Grumont RJ; Hochrein H; Fuchsberger M; Gugasyan R; Vremec D; Shortman K; Gerondakis S. 2005. Distinct roles for the NF-kappaB1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals. Blood 106(10):3457-64. [PubMed: 16037393]  [MGI Ref ID J:124073]

O'donnell SM; Hansberger MW; Connolly JL; Chappell JD; Watson MJ; Pierce JM; Wetzel JD; Han W; Barton ES; Forrest JC; Valyi-Nagy T; Yull FE; Blackwell TS; Rottman JN; Sherry B; Dermody TS. 2005. Organ-specific roles for transcription factor NF-kappaB in reovirus-induced apoptosis and disease. J Clin Invest 115(9):2341-2350. [PubMed: 16100570]  [MGI Ref ID J:100906]

Oakley F; Mann J; Nailard S; Smart DE; Mungalsingh N; Constandinou C; Ali S; Wilson SJ; Millward-Sadler H; Iredale JP; Mann DA. 2005. Nuclear Factor-{kappa}B1 (p50) Limits the Inflammatory and Fibrogenic Responses to Chronic Injury. Am J Pathol 166(3):695-708. [PubMed: 15743782]  [MGI Ref ID J:96721]

Ouaaz F; Arron J; Zheng Y; Choi Y; Beg AA. 2002. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 16(2):257-70. [PubMed: 11869686]  [MGI Ref ID J:113514]

Paxian S; Merkle H; Riemann M; Wilda M; Adler G; Hameister H; Liptay S; Pfeffer K; Schmid RM. 2002. Abnormal organogenesis of Peyer's patches in mice deficient for NF-kappaB1, NF-kappaB2, and Bcl-3. Gastroenterology 122(7):1853-68. [PubMed: 12055593]  [MGI Ref ID J:77049]

Pelletier M; Girard D. 2006. Differential effects of IL-15 and IL-21 in myeloid (CD11b+) and lymphoid (CD11b-) bone marrow cells. J Immunol 177(1):100-8. [PubMed: 16785504]  [MGI Ref ID J:134407]

Pohl T; Gugasyan R; Grumont RJ; Strasser A; Metcalf D; Tarlinton D; Sha W; Baltimore D; Gerondakis S. 2002. The combined absence of NF-kappa B1 and c-Rel reveals that overlapping roles for these transcription factors in the B cell lineage are restricted to the activation and function of mature cells. Proc Natl Acad Sci U S A 99(7):4514-9. [PubMed: 11930006]  [MGI Ref ID J:91684]

Razeghi P; Wang ME; Youker KA; Golfman L; Stepkowski S; Taegtmeyer H. 2007. Lack of NF-kappaB1 (p105/p50) attenuates unloading-induced downregulation of PPARalpha and PPARalpha-regulated gene expression in rodent heart. Cardiovasc Res 74(1):133-9. [PubMed: 17276423]  [MGI Ref ID J:119766]

Robinson MJ; Beinke S; Kouroumalis A; Tsichlis PN; Ley SC. 2007. Phosphorylation of TPL-2 on serine 400 is essential for lipopolysaccharide activation of extracellular signal-regulated kinase in macrophages. Mol Cell Biol 27(21):7355-64. [PubMed: 17709378]  [MGI Ref ID J:129052]

Rodriguez-Galan MC; Bream JH; Farr A; Young HA. 2005. Synergistic effect of IL-2, IL-12, and IL-18 on thymocyte apoptosis and Th1/Th2 cytokine expression. J Immunol 174(5):2796-804. [PubMed: 15728489]  [MGI Ref ID J:97710]

Saccani A; Schioppa T; Porta C; Biswas SK; Nebuloni M; Vago L; Bottazzi B; Colombo MP; Mantovani A; Sica A. 2006. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 66(23):11432-40. [PubMed: 17145890]  [MGI Ref ID J:116212]

Schwarz EM; Badorff C; Hiura TS; Wessely R; Badorff A; Verma IM; Knowlton KU. 1998. NF-kappaB-mediated inhibition of apoptosis is required for encephalomyocarditis virus virulence: a mechanism of resistance in p50 knockout mice. J Virol 72(7):5654-60. [PubMed: 9621024]  [MGI Ref ID J:120576]

Sha WC; Liou HC; Tuomanen EI; Baltimore D. 1995. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 80(2):321-30. [PubMed: 7834752]  [MGI Ref ID J:37184]

Shi M; Deng W; Bi E; Mao K; Ji Y; Lin G; Wu X; Tao Z; Li Z; Cai X; Sun S; Xiang C; Sun B. 2008. TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat Immunol 9(4):369-77. [PubMed: 18345001]  [MGI Ref ID J:133259]

Sivakumar V; Hammond KJ; Howells N; Pfeffer K; Weih F. 2003. Differential requirement for Rel/nuclear factor kappa B family members in natural killer T cell development. J Exp Med 197(12):1613-21. [PubMed: 12810684]  [MGI Ref ID J:120660]

Snapper CM; Zelazowski P; Rosas FR; Kehry MR; Tian M; Baltimore D; Sha WC. 1996. B cells from p50/NF-kappa B knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching. J Immunol 156(1):183-91. [PubMed: 8598461]  [MGI Ref ID J:30268]

Stanic AK; Bezbradica JS; Park JJ; Matsuki N; Mora AL; Van Kaer L; Boothby MR; Joyce S. 2004. NF-kappa B controls cell fate specification, survival, and molecular differentiation of immunoregulatory natural T lymphocytes. J Immunol 172(4):2265-73. [PubMed: 14764695]  [MGI Ref ID J:88049]

Stanic AK; Bezbradica JS; Park JJ; Van Kaer L; Boothby MR; Joyce S. 2004. Cutting edge: the ontogeny and function of Va14Ja18 natural T lymphocytes require signal processing by protein kinase C theta and NF-kappa B. J Immunol 172(8):4667-71. [PubMed: 15067039]  [MGI Ref ID J:89129]

Tato CM; Mason N; Artis D; Shapira S; Caamano JC; Bream JH; Liou HC; Hunter CA. 2006. Opposing roles of NF-{kappa}B family members in the regulation of NK cell proliferation and production of IFN-{gamma}. Int Immunol 18(4):505-13. [PubMed: 16481345]  [MGI Ref ID J:107069]

TeKippe M; Harrison DE; Chen J. 2003. Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol 31(6):521-7. [PubMed: 12829028]  [MGI Ref ID J:115677]

Tharappel JC; Nalca A; Owens AB; Ghabrial L; Konz EC; Glauert HP; Spear BT. 2003. Cell proliferation and apoptosis are altered in mice deficient in the NF-kappaB p50 subunit after treatment with the peroxisome proliferator ciprofibrate. Toxicol Sci 75(2):300-8. [PubMed: 12883078]  [MGI Ref ID J:126216]

Tharappel JC; Spear BT; Glauert HP. 2008. Effect of phenobarbital on hepatic cell proliferation and apoptosis in mice deficient in the p50 subunit of NF-kappaB. Toxicol Appl Pharmacol 226(3):338-44. [PubMed: 17963809]  [MGI Ref ID J:132189]

Thomas HE; Angstetra E; Fernandes RV; Mariana L; Irawaty W; Jamieson EL; Dudek NL; Kay TW. 2006. Perturbations in nuclear factor-kappaB or c-Jun N-terminal kinase pathways in pancreatic beta cells confer susceptibility to cytokine-induced cell death. Immunol Cell Biol 84(1):20-7. [PubMed: 16277639]  [MGI Ref ID J:105855]

Thomas PG; Carter MR; Da'dara AA; DeSimone TM; Harn DA. 2005. A helminth glycan induces APC maturation via alternative NF-kappa B activation independent of I kappa B alpha degradation. J Immunol 175(4):2082-90. [PubMed: 16081774]  [MGI Ref ID J:107518]

Tomczak MF; Erdman SE; Davidson A; Wang YY; Nambiar PR; Rogers AB; Rickman B; Luchetti D; Fox JG; Horwitz BH. 2006. Inhibition of Helicobacter hepaticus-induced colitis by IL-10 requires the p50/p105 subunit of NF-kappa B. J Immunol 177(10):7332-9. [PubMed: 17082652]  [MGI Ref ID J:140612]

Tomczak MF; Gadjeva M; Wang YY; Brown K; Maroulakou I; Tsichlis PN; Erdman SE; Fox JG; Horwitz BH. 2006. Defective activation of ERK in macrophages lacking the p50/p105 subunit of NF-kappaB is responsible for elevated expression of IL-12 p40 observed after challenge with Helicobacter hepaticus. J Immunol 176(2):1244-51. [PubMed: 16394015]  [MGI Ref ID J:126439]

Wang Y; Meng A; Lang H; Brown SA; Konopa JL; Kindy MS; Schmiedt RA; Thompson JS; Zhou D. 2004. Activation of nuclear factor kappaB In vivo selectively protects the murine small intestine against ionizing radiation-induced damage. Cancer Res 64(17):6240-6. [PubMed: 15342410]  [MGI Ref ID J:92410]

Wang YJ; Wang JT; Fan QX; Geng JG. 2007. Andrographolide inhibits NF-kappaBeta activation and attenuates neointimal hyperplasia in arterial restenosis. Cell Res 17(11):933-41. [PubMed: 17943075]  [MGI Ref ID J:133635]

Weih F; Durham SK; Barton DS; Sha WC; Baltimore D; Bravo R. 1996. Both multiorgan inflammation and myeloid hyperplasia in RelB-deficient mice are T cell dependent. J Immunol 157(9):3974-9. [PubMed: 8892630]  [MGI Ref ID J:110829]

Weih F; Durham SK; Barton DS; Sha WC; Baltimore D; Bravo R. 1997. p50-NF-kappaB complexes partially compensate for the absence of RelB: severely increased pathology in p50(-/-)relB(-/-) double-knockout mice. J Exp Med 185(7):1359-70. [PubMed: 9104822]  [MGI Ref ID J:39508]

Wuerffel RA; Ma L; Kenter AL. 2001. NF-kappa B p50-dependent in vivo footprints at Ig S gamma 3 DNA are correlated with mu-->gamma 3 switch recombination. J Immunol 166(7):4552-9. [PubMed: 11254712]  [MGI Ref ID J:123765]

Xing L; Carlson L; Story B; Tai Z; Keng P; Siebenlist U; Boyce BF. 2003. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. J Bone Miner Res 18(2):260-9. [PubMed: 12568403]  [MGI Ref ID J:111245]

Yamamoto M; Yamazaki S; Uematsu S; Sato S; Hemmi H; Hoshino K; Kaisho T; Kuwata H; Takeuchi O; Takeshige K; Saitoh T; Yamaoka S; Yamamoto N; Yamamoto S; Muta T; Takeda K; Akira S. 2004. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature 430(6996):218-22. [PubMed: 15241416]  [MGI Ref ID J:91297]

Yamashita T; Yao Z; Li F; Zhang Q; Badell IR; Schwarz EM; Takeshita S; Wagner EF; Noda M; Matsuo K; Xing L; Boyce BF. 2007. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 282(25):18245-53. [PubMed: 17485464]  [MGI Ref ID J:123379]

Yang G; Abate A; George AG; Weng YH; Dennery PA. 2004. Maturational differences in lung NF-kappaB activation and their role in tolerance to hyperoxia. J Clin Invest 114(5):669-78. [PubMed: 15343385]  [MGI Ref ID J:92596]

Yang L; Cohn L; Zhang DH; Homer R; Ray A; Ray P. 1998. Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation. J Exp Med 188(9):1739-50. [PubMed: 9802985]  [MGI Ref ID J:50763]

Yao Z; Xing L; Qin C; Schwarz EM; Boyce BF. 2008. Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism. J Biol Chem 283(15):9917-24. [PubMed: 18250170]  [MGI Ref ID J:135323]

Yilmaz ZB; Weih DS; Sivakumar V; Weih F. 2003. RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J 22(1):121-30. [PubMed: 12505990]  [MGI Ref ID J:81255]

Yu Z; Zhou D; Bruce-Keller AJ; Kindy MS; Mattson MP. 1999. Lack of the p50 subunit of nuclear factor-kappaB increases the vulnerability of hippocampal neurons to excitotoxic injury. J Neurosci 19(20):8856-65. [PubMed: 10516305]  [MGI Ref ID J:119905]

Yu Z; Zhou D; Cheng G; Mattson MP. 2000. Neuroprotective role for the p50 subunit of NF-kappaB in an experimental model of Huntington's disease. J Mol Neurosci 15(1):31-44. [PubMed: 11211235]  [MGI Ref ID J:117914]

Zarnegar B; He JQ; Oganesyan G; Hoffmann A; Baltimore D; Cheng G. 2004. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci U S A 101(21):8108-13. [PubMed: 15148378]  [MGI Ref ID J:90663]

Zelazowski P; Shen Y; Snapper CM. 2000. NF-kappaB/p50 and NF-kappaB/c-Rel differentially regulate the activity of the 3'alphaE-hsl,2 enhancer in normal murine B cells in an activation-dependent manner. Int Immunol 12(8):1167-72. [PubMed: 10917891]  [MGI Ref ID J:110506]

Zhan Y; Gerondakis S; Coghill E; Bourges D; Xu Y; Brady JL; Lew AM. 2008. Glucocorticoid-induced TNF receptor expression by T cells is reciprocally regulated by NF-kappaB and NFAT. J Immunol 181(8):5405-13. [PubMed: 18832697]  [MGI Ref ID J:140766]

Zhang J; Warren MA; Shoemaker SF; Ip MM. 2007. NFkappaB1/p50 is not required for tumor necrosis factor-stimulated growth of primary mammary epithelial cells: implications for NFkappaB2/p52 and RelB. Endocrinology 148(1):268-78. [PubMed: 17008396]  [MGI Ref ID J:129561]

Zhang Q; Guo R; Lu Y; Zhao L; Zhou Q; Schwarz EM; Huang J; Chen D; Jin ZG; Boyce BF; Xing L. 2008. VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism. J Biol Chem 283(19):13491-9. [PubMed: 18359770]  [MGI Ref ID J:137099]

Zhu M; Chin RK; Christiansen PA; Lo JC; Liu X; Ware C; Siebenlist U; Fu YX. 2006. NF-kappaB2 is required for the establishment of central tolerance through an Aire-dependent pathway. J Clin Invest 116(11):2964-71. [PubMed: 17039258]  [MGI Ref ID J:115011]

dos Santos NR; Williame M; Gachet S; Cormier F; Janin A; Weih D; Weih F; Ghysdael J. 2008. RelB-dependent stromal cells promote T-cell leukemogenesis. PLoS ONE 3(7):e2555. [PubMed: 18596915]  [MGI Ref ID J:137965]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX11

Colony Maintenance

Breeding & Husbandry	When maintaining a live colony, these mice are bred as homozygotes.
Mating System	Homozygote x Homozygote         (Female x Male)
Diet Information	LabDiet® 5K52/5K67

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Supply Details

Standard Supply

Repository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of ~nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within 48 hours of order placement.

Supply Notes

Usually shipped between four and eight weeks of age. This strain is included in the Induced Mutant Resource Colony collection.

Control Information

	Control
	000664 C57BL/6J	(approximate)
Considerations for Choosing Controls
USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
International - Control Pricing Information for Genetically Engineered Mutant Strains.

General Terms and Conditions

See Terms of Use

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX^® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX^® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX^® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

---

Ordering and Purchasing Information

      Purchasing Information
      JAX^® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form

Terms of Use

Terms of Use

General Terms and Conditions

For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.

Contact information

General inquiries

Contracts Administration

phone:	207-288-6470
fax:	207-288-6655

JAX^® Mice & Services Conditions of Use

“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.

No Liability

In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.

MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.

Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.